Biotech entity
All 2 tracked stories fall under one category: pharma. Of the tracked stories, 1 of 2 also mention Avance Nerve Graft, the most common co-covered peer. The 33-day window averages about 0.4 stories each week. The 5.5 average consequence score is below the beat benchmark of 6.1 in the same window.
Last mentioned: Mar 22, 2026
Entity pulse
Coverage balance Positive coverage leads. Positive coverage exceeds negative coverage by 50 percentage points.
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
All 2 tracked stories fall under one category: pharma. Of the tracked stories, 1 of 2 also mention Avance Nerve Graft, the most common co-covered peer. The 33-day window averages about 0.4 stories each week. The 5.5 average consequence score is below the beat benchmark of 6.1 in the same window. Source depth averages 4 original sources per story, versus 3.4 across the same-window beat baseline. AtriCure appears in 2 tracked Biotech stories published from February 18, 2026 through March 22, 2026.
Computed from the 2 stories linked to this entity, with beat comparisons drawn from all 421 Biotech stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering AtriCure. Shared-story counts are live from our verified record — not editorial picks.
DAFNA Capital Management reduced its position in Axogen by approximately $6.5 million during the fourth quarter of 2025, a move that follows a significant 71% surge in the company's stock price. Despite the trim, Axogen remains a significant holding for the fund as the company continues to see 20% revenue growth driven by its peripheral nerve repair portfolio.
Insulet and AtriCure reported strong quarterly results, both beating analyst estimates on top and bottom lines. These results highlight robust demand for insulin delivery systems and atrial fibrillation treatments despite broader macroeconomic pressures.
Source: Seeking Alpha · Seeking Alpha
AtriCure is linked from 2 stories on this site, each scored at or above our 35% relevance threshold — see how these pages are built.
See something wrong on this page — a misattributed entity, a wrong stat, a broken source link? Report a data issue.
